Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05)
Status:
Completed
Trial end date:
2021-07-10
Target enrollment:
Participant gender:
Summary
This study is a phase 1, dose finding, open-label study in patients with relapsed/refractory
diffuse large B-cell lymphoma (DLBCL). This is a dose escalating study to define the maximum
tolerable dose of lutetium (177Lu)-lilotomab satetraxetan (Betalutin®) in DLBCL patients who
are not eligible for autologous stem cell transplant. The study will also assess safety and
toxicity, pharmacokinetics, biodistribution and efficacy.